{"id":49961,"date":"2025-12-04T19:38:44","date_gmt":"2025-12-04T11:38:44","guid":{"rendered":"https:\/\/flcube.com\/?p=49961"},"modified":"2025-12-04T19:38:45","modified_gmt":"2025-12-04T11:38:45","slug":"gene-mink-car-nk-bcma-therapy-wins-china-approval-for-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49961","title":{"rendered":"Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma"},"content":{"rendered":"\n<p><strong>Beijing Gene Mink Biotechnology<\/strong> announced that its self-developed <strong>QM103 Cell Injection<\/strong>, a <strong>BCMA\u2011targeted CAR\u2011NK cell therapy<\/strong>, was granted <strong>tacit approval<\/strong> for clinical trials by China&#8217;s National Medical Products Administration (NMPA) (Acceptance No.: CXSL2500762), marking the <strong>first CAR\u2011NK product approved for trials in China<\/strong> for <strong>relapsed\/refractory multiple myeloma (RRMM)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-product-profile\">Regulatory Milestone &amp; Product Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Beijing Gene Mink Biotechnology<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>QM103 Cell Injection<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>NMPA tacit approval (IND)<\/td><\/tr><tr><td><strong>Acceptance No.<\/strong><\/td><td>CXSL2500762<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Relapsed\/Refractory Multiple Myeloma (RRMM)<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>First BCMA\u2011targeted CAR\u2011NK therapy approved for clinical trials in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-breakthrough-amp-manufacturing-innovation\">Technology Breakthrough &amp; Manufacturing Innovation<\/h2>\n\n\n\n<p>QM103 is developed on Gene Mink&#8217;s proprietary platform addressing three critical CAR\u2011NK manufacturing bottlenecks:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Expansion Challenge<\/strong>: Traditional NK cell expansion achieves only hundreds\u2011fold growth with insufficient purity<\/li>\n\n\n\n<li><strong>Gene Mink Solution<\/strong>: <strong>Serum\u2011free, feeder\u2011cell\u2011free expansion system<\/strong><\/li>\n\n\n\n<li><strong>Performance<\/strong>:<\/li>\n\n\n\n<li><strong>Tens of thousands\u2011fold NK cell expansion<\/strong><\/li>\n\n\n\n<li><strong>>98% NK cell purity<\/strong><\/li>\n\n\n\n<li><strong>Effective resolution of large\u2011scale CAR\u2011NK manufacturing constraints<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market Parameter<\/th><th>Global Status<\/th><th>China Opportunity<\/th><\/tr><\/thead><tbody><tr><td><strong>CAR\u2011NK Products<\/strong><\/td><td>No products formally launched globally<\/td><td>QM103 first to enter clinical trials<\/td><\/tr><tr><td><strong>Industry Stage<\/strong><\/td><td>Most development remains preclinical<\/td><td>Gene Mink leads manufacturing innovation<\/td><\/tr><tr><td><strong>Multiple Myeloma Incidence<\/strong><\/td><td>~180,000 new cases globally (2024)<\/td><td>~20,000 new cases in China annually<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>CAR\u2011T therapies (BCMA\u2011targeted)<\/td><td>High cost, complex logistics, toxicity concerns<\/td><\/tr><tr><td><strong>CAR\u2011NK Advantages<\/strong><\/td><td>Off\u2011the\u2011shelf, lower cost, reduced toxicity<\/td><td>Addresses key barriers to patient access<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook-amp-next-steps\">Strategic Outlook &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Development<\/strong>: Phase 1 trial initiation expected Q1\u202f2026<\/li>\n\n\n\n<li><strong>Manufacturing Scale<\/strong>: Proprietary platform enables cost\u2011effective production for commercial scale<\/li>\n\n\n\n<li><strong>First\u2011Mover Advantage<\/strong>: Positions Gene Mink as pioneer in China&#8217;s emerging cell therapy market<\/li>\n\n\n\n<li><strong>Global Potential<\/strong>: China IND approval may support future US\/EU development pathways via manufacturing data<\/li>\n\n\n\n<li><strong>Investment Appeal<\/strong>: Platform technology applicable to other oncology and autoimmune indications<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding QM103 development timelines, clinical outcomes, and manufacturing scalability. Actual results may differ due to clinical, regulatory, and competitive uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Beijing Gene Mink Biotechnology announced that its self-developed QM103 Cell Injection, a BCMA\u2011targeted CAR\u2011NK cell&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49964,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[77,62,4488],"class_list":["post-49961","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cell-therapy","tag-clinical-trial-approval-initiation","tag-gene-mink-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing Gene Mink Biotechnology announced that its self-developed QM103 Cell Injection, a BCMA\u2011targeted CAR\u2011NK cell therapy, was granted tacit approval for clinical trials by China&#039;s National Medical Products Administration (NMPA) (Acceptance No.: CXSL2500762), marking the first CAR\u2011NK product approved for trials in China for relapsed\/refractory multiple myeloma (RRMM).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49961\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma\" \/>\n<meta property=\"og:description\" content=\"Beijing Gene Mink Biotechnology announced that its self-developed QM103 Cell Injection, a BCMA\u2011targeted CAR\u2011NK cell therapy, was granted tacit approval for clinical trials by China&#039;s National Medical Products Administration (NMPA) (Acceptance No.: CXSL2500762), marking the first CAR\u2011NK product approved for trials in China for relapsed\/refractory multiple myeloma (RRMM).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49961\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-04T11:38:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-04T11:38:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0407.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49961#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49961\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma\",\"datePublished\":\"2025-12-04T11:38:44+00:00\",\"dateModified\":\"2025-12-04T11:38:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49961\"},\"wordCount\":344,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49961#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0407.webp\",\"keywords\":[\"Cell-therapy\",\"Clinical trial approval \\\/ initiation\",\"Gene Mink Biotechnology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49961#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49961\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49961\",\"name\":\"Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49961#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49961#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0407.webp\",\"datePublished\":\"2025-12-04T11:38:44+00:00\",\"dateModified\":\"2025-12-04T11:38:45+00:00\",\"description\":\"Beijing Gene Mink Biotechnology announced that its self-developed QM103 Cell Injection, a BCMA\u2011targeted CAR\u2011NK cell therapy, was granted tacit approval for clinical trials by China's National Medical Products Administration (NMPA) (Acceptance No.: CXSL2500762), marking the first CAR\u2011NK product approved for trials in China for relapsed\\\/refractory multiple myeloma (RRMM).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49961#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49961\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49961#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0407.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0407.webp\",\"width\":1080,\"height\":608,\"caption\":\"Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49961#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry","description":"Beijing Gene Mink Biotechnology announced that its self-developed QM103 Cell Injection, a BCMA\u2011targeted CAR\u2011NK cell therapy, was granted tacit approval for clinical trials by China's National Medical Products Administration (NMPA) (Acceptance No.: CXSL2500762), marking the first CAR\u2011NK product approved for trials in China for relapsed\/refractory multiple myeloma (RRMM).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49961","og_locale":"en_US","og_type":"article","og_title":"Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma","og_description":"Beijing Gene Mink Biotechnology announced that its self-developed QM103 Cell Injection, a BCMA\u2011targeted CAR\u2011NK cell therapy, was granted tacit approval for clinical trials by China's National Medical Products Administration (NMPA) (Acceptance No.: CXSL2500762), marking the first CAR\u2011NK product approved for trials in China for relapsed\/refractory multiple myeloma (RRMM).","og_url":"https:\/\/flcube.com\/?p=49961","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-04T11:38:44+00:00","article_modified_time":"2025-12-04T11:38:45+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0407.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49961#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49961"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma","datePublished":"2025-12-04T11:38:44+00:00","dateModified":"2025-12-04T11:38:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49961"},"wordCount":344,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49961#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0407.webp","keywords":["Cell-therapy","Clinical trial approval \/ initiation","Gene Mink Biotechnology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49961#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49961","url":"https:\/\/flcube.com\/?p=49961","name":"Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49961#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49961#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0407.webp","datePublished":"2025-12-04T11:38:44+00:00","dateModified":"2025-12-04T11:38:45+00:00","description":"Beijing Gene Mink Biotechnology announced that its self-developed QM103 Cell Injection, a BCMA\u2011targeted CAR\u2011NK cell therapy, was granted tacit approval for clinical trials by China's National Medical Products Administration (NMPA) (Acceptance No.: CXSL2500762), marking the first CAR\u2011NK product approved for trials in China for relapsed\/refractory multiple myeloma (RRMM).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49961#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49961"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49961#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0407.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0407.webp","width":1080,"height":608,"caption":"Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49961#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0407.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49961"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49961\/revisions"}],"predecessor-version":[{"id":49966,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49961\/revisions\/49966"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49964"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}